SAVARA INC

NASDAQ: SVRA (Savara, Inc.)

Kemas kini terakhir: 13 May, 5:44PM

2.82

-0.04 (-1.40%)

  • 1H -1.40%
  • 5H -8.14%
  • 1B -11.88%
  • 6B -14.67%
  • Tahun Ke Tarikh -8.14%
  • 1T -31.39%
  • 5T 16.53%
Penutupan Terdahulu 2.86
Buka 2.92
Jumlah Dagangan 4,590,394
Purata Dagangan (3B) 1,023,811
Modal Pasaran 490,829,440
Harga / Buku (P/B) 3.32
Julat 52 Minggu
2.26 (-20%) — 5.34 (89%)
Tarikh Pendapatan 7 May 2025 - 12 May 2025
EPS Cair (TTM) -0.480
Jumlah Hutang/Ekuiti (D/E MRQ) 15.66%
Nisbah Semasa (MRQ) 13.73
Aliran Tunai Operasi (OCF TTM) -89.09 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -51.50 M
Pulangan Atas Aset (ROA TTM) -32.78%
Pulangan Atas Ekuiti (ROE TTM) -61.50%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Savara, Inc. Menurun Menurun

AISkor Stockmoo

1.9
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga 3.5
Purata Bergerak Teknikal 5.0
Osilator Teknikal -2.5
Purata 1.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SVRA 491 M - - 3.32
RVMD 7 B - - 3.31
AKRO 4 B - - 3.41
CRNX 3 B - - 2.12
LGND 2 B - - 2.55
KYMR 2 B - - 2.38

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 5.23%
% Dimiliki oleh Institusi 97.25%
10.7510.758.508.506.256.254.004.001.751.75Harga Sasaran MedianQ2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
2.26 (-20%) — 5.34 (89%)
Julat Harga Sasaran
2.00 (-29%) — 8.00 (183%)
Tinggi 8.00 (Guggenheim, 183.69%) Beli
Median 4.50 (59.57%)
Rendah 2.00 (HC Wainwright & Co., -29.08%) Pegang
2.00 (Evercore ISI Group, -29.08%) Pegang
Purata 4.75 (68.44%)
Jumlah 2 Beli, 2 Pegang
Harga Purata @ Panggilan 2.84
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 29 May 2025 2.00 (-29.08%) Pegang 2.84
28 Mar 2025 6.00 (112.77%) Beli 2.91
Evercore ISI Group 28 May 2025 2.00 (-29.08%) Pegang 2.84
Guggenheim 28 May 2025 8.00 (183.69%) Beli 2.84
Wells Fargo 28 May 2025 7.00 (148.23%) Beli 2.84

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
22 May 2025 Pengumuman Savara Announces Participation in Jefferies Global Healthcare Conference
18 May 2025 Pengumuman Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
13 May 2025 Pengumuman Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
12 May 2025 Pengumuman Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
01 May 2025 Pengumuman Savara Announces Participation in the Upcoming Citizens Life Sciences Conference 
11 Apr 2025 Pengumuman Savara Announces New Employment Inducement Grant
07 Apr 2025 Pengumuman Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
27 Mar 2025 Pengumuman Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
26 Mar 2025 Pengumuman Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
26 Mar 2025 Pengumuman Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
17 Mar 2025 Pengumuman Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
06 Mar 2025 Pengumuman Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
03 Mar 2025 Pengumuman Savara Announces Participation in the Leerink Global Healthcare Conference
Papar semua
3.243.243.073.072.902.902.732.732.562.56May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0600.0600.0400.0400.0200.0200.0000.000-0.020-0.020MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda